keyword
MENU ▼
Read by QxMD icon Read
search

atrial fibrillation cordarone

keyword
https://www.readbyqxmd.com/read/26432747/dabigatran-for-left-ventricular-thrombus
#1
Satishkumar Kolekar, Chandrashekhar Munjewar, Satyavan Sharma
Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued due to marked fluctuations in INR. Transthoracic Echocardiography (TTE) revealed a mobile mass in the left ventricle. He was treated with Dabigatran 110mg twice a day for 4 months without any bleeding or embolic episode and complete resolution of thrombus...
September 2015: Indian Heart Journal
https://www.readbyqxmd.com/read/22173456/safety-of-dronedarone-multaq
#2
(no author information available yet)
Dronedarone (Multaq-Sanofi), an analog of amiodarone, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial flutter. Amiodarone (Cordarone, and others) is more effective for this indication, but its use is often limited by its adverse effects, including thyroid and pulmonary toxicity.
December 12, 2011: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/21364162/dronedarone-for-atrial-fibrillation-how-does-it-compare-with-amiodarone
#3
COMPARATIVE STUDY
Neelima Penugonda, Adam Mohmand-Borkowski, James F Burke
Dronedarone (Multaq), an analogue of amiodarone (Cordarone), was designed to cause fewer adverse effects than the parent compound. Studies have indeed shown dronedarone to be safer than amiodarone, but less effective. Its official indication is to reduce the risk of hospitalization in patients with paroxysmal or persistent atrial fibrillation or atrial flutter and other cardiovascular risk factors, reflecting the parameters of its effectiveness in clinical trials.
March 2011: Cleveland Clinic Journal of Medicine
https://www.readbyqxmd.com/read/21266300/anaphylactic-shock-due-to-intravenous-amiodarone
#4
İbrahim Halil Kurt, Fatih Yalcin
A 24-year-old male patient was admitted to the coronary intensive care unit with atrial fibrillation with rapid ventricular response. He was given amiodarone (Cordarone 150 mg i.v., Sanofi-Aventis) intravenous loading dose of 300 mg in 100 mL dextrose 5% in water (D5W) over 1 hour, followed by a maintenance dose of 900 mg in 500 mL D5W for infusion up to 24 hours. At the emergency department, the patient was conscious and cooperative; his pretreatment arterial blood pressure was 120/80 mm Hg, and the arrhythmic tachycardia was 145 per minute...
January 2012: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/19798011/dronedarone-multaq-for-atrial-fibrillation
#5
(no author information available yet)
Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
October 5, 2009: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/17525498/-dynamics-of-echocardiographic-changes-and-the-tactic-of-optimal-therapy-in-patients-with-atrial-fibrillation-with-chronical-heart-failure
#6
G V Abuladze, N A Dzhindzholiia, I A Dzhashi, E V Narsiia, L A Gudzhedzhiani
The aim of the article was to assess the efficacy of treatment of atrial fibrillation (AE) and congestive heart failure (CHF) with Enalapril in combination with Cordaron. For this reason 62 patients from 37 to 70 years old (mean age 54, 6 +/- 6,1) with CHF (class II-III NYHA) and persistent AF underwent the medical treatment. The suggested scheme of treatment improved HF functional class by NYHA, raised anti reactive effectiveness and favorably influenced on the diastolic function of the LV in this type of patients...
April 2007: Georgian Medical News
https://www.readbyqxmd.com/read/17523411/-long-qt-syndrome-induced-by-cordaron-and-quinidine
#7
E V Mironchik, T S Dolgosheĭ, T G Liskovich, G A Madeshkina, A B Kokhkovski, A D Tyshchenko
The article presents an observation of a 63-year-old female patient suffering from arterial hypertension, coronary artery disease complicated by a persistent form of atrial fibrillation during 1.5 months, and hereditary Minkowski-Chauffard hemolytic anemia. Treatment with cordaron proved to be ineffective, while oral administration of quinidin in a dose of 1 gr (0.2 gr five times a day) led to restoration of sinus rhythm. However, long QT interval syndrome complicated by ventricular tachycardic paroxysms of torsade de pointes type developed; later it transformed into ventricular fibrillation...
2007: Klinicheskaia Meditsina
https://www.readbyqxmd.com/read/17478949/-characterizations-of-atrial-contractions-triggering-paroxysmal-atrial-fibrillation-and-the-effect-of-atrial-fibrillation-prevention-pacing
#8
Yong-Hong Guo, Qi-Ming Liu, Shu-Shan Qi, Sheng-Hua Zhou
OBJECTIVE: To evaluate the electrocardiographic characterizations of atrial contractions(AC) triggering paroxysmal atrial fibrillation(AF), and to explore the effects of AF prevention pacing on their electrocardiographic characterizations. METHODS: Twenty-four patients with the implantation of AF therapy pacemaker(Vitatron 900E) were analyzed by AC triggering paroxysmal AF with Holter monitoring in the study. AC compluing interval, compensatory pause and frequency 2 minutes before the AF or during the AC were compared between the induced paroxysmal AF group and noinduced paroxysmal AF group, and the preventive effect of AF on the post-PAC response program was investigated...
April 2007: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/16624772/-effect-of-oral-cordarone-in-reversing-persistent-atrial-fibrillation
#9
Fu Zhao, Shao-xian Feng, Ping Zhao, Hong Ma
OBJECTIVE: To observe the efficacy and safety of oral cordarone dir reversing persistent atrial fibrillation (AF). METHODS; Eighty-two symptomatic chronic AF out-patients without history of acute diseases or severe hepatic/thyroid dysfunction were given oral cordarone at the loading dose of 200 mg thrice a day for 1-4 weeks followed by a twice-daily administration for another 1-4 weeks, with the maintenance dose of 200 or 100 mg once a day. The incidence of stroke and cardiac events and the mortality rate were compared between 43 patients with restored rhythm on cordarone and 39 patients on digoxin and/or betaloc for ventricular rhythm control...
April 2006: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/16476650/acute-onset-of-halos-and-glare-bilateral-corneal-epithelial-edema-with-cystic-eruptions-atypical-presentation-of-amiodarone-keratopathy
#10
John M Dovie, Andrew S Gurwood
BACKGROUND: Amiodarone (Cordarone; Wyeth, Ayerst, New York) is a potassium channel blocking antiarrythmal medication indicated for recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia. Chemically, it is classified as an iodinated benzofuran derivate antiarrythmal drug not chemically related to any other available antiarrhythmic drug. Documented side effects of amiodarone include neurologic, gastrointestinal, dermatologic, cardiovascular, and ophthalmic...
February 2006: Optometry: Journal of the American Optometric Association
https://www.readbyqxmd.com/read/16148376/-optimal-approach-to-the-treatment-of-atrial-fibrillation-in-patients-with-chronic-heart-failure
#11
G V Abuladze, B Sh Burdiashvili, I M Dzhshi, E V Narsiia, D A Kantariia
Atrial fibrillation (AF) is one of the most frequently seen arrhythmia. Optimal strategy of its treatment still remains a serious problem. The goal of the investigation was the evaluation of the efficacy of combined treatment of AF with Cordaron and ACE inhibitor Diroton (lizinopril) (D) in patients with chronic heart failure (CHF). 29 patients (32-78 years old) with persistive AF and CHF (II - III class NYHA) were under observation. The treatment with C 200 - 300 mg/day and D 5 -10mg/day for 12 weeks resulted in improvement of clinical status of the patients, improvement in functional class of CHF, decrease in frequency of recurrences of AF in comparison with patients who were not given ACE inhibitor...
July 2005: Georgian Medical News
https://www.readbyqxmd.com/read/11486158/efficacy-of-low-dose-amiodarone-in-the-prevention-of-paroxysmal-atrial-fibrillation-resistant-to-type-ia-antiarrhythmic-drugs
#12
N Z Kerin, K Faitel, I A Kerin, L Quinones, R J Stomel
The efficacy and safety of low-dose amiodarone (Cordarone; Wyeth-Ayerst, Philadelphia, PA) was assessed in 62 symptomatic patients with paroxysmal atrial fibrillation who were resistant to at least two types of IA drugs. The beneficial response to this treatment was defined as a reduction in paroxysmal atrial fibrillation of greater than or equal to 50% within 1 month. Of the 42 patients (67.7%) who were responders, 39 (62.9%) were completely free of episodes. Intolerable side effects were seen in 12 patients (19...
August 2000: American Journal of Therapeutics
https://www.readbyqxmd.com/read/10225107/-antiarrhythmic-efficacy-of-cordarone-during-neurogenic-atrial-fibrillation
#13
I L Cherednik, Iu R Sheĭkh-Zade
No abstract text is available yet for this article.
March 1999: Biulleten' Eksperimental'noĭ Biologii i Meditsiny
https://www.readbyqxmd.com/read/9821233/-combined-use-of-left-atrial-transesophageal-pacing-and-cordarone-in-atrial-flutter
#14
COMPARATIVE STUDY
G V Matiushin, V A Shul'man, A I Balog, S E Golovenkin, O V Smirnova
AIM: To investigate the effectiveness of superfrequent transesophageal left atrial stimulation (TLAS) and its combination with cordarone in management of atrial flutter (AF). MATERIALS AND METHODS: 650 patients with paroxysmal AF underwent TLAS. The paroxysm duration varied from 1 hour to 1 month. In 312 patients TLAS was performed prior to treatment with antiarrhythmic drugs (group 1), in 338 patients--after intravenous administration of cordarone (group 2). RESULTS: Superfrequent TLAS has restored sinus rhythm (SR) in 85(27...
1998: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/8497770/-dangerous-arrhythmias
#15
REVIEW
M Gertsch, J Fuhrer
The usual frequent tachyarrhythmias well known to the specialists in internal medicine, such as ventricular tachycardia and ventricular fibrillation, are not discussed in this publication; nor are the bradycardias connected with the sick sinus syndrome or with atrioventricular block of higher degrees (with one exception). In the first section a stratification of the risk after myocardial infarction is presented including the therapeutic implications. Severely reduced left ventricular function is of most negative prognostic value...
May 1, 1993: Schweizerische Medizinische Wochenschrift
https://www.readbyqxmd.com/read/8059388/-the-optimization-of-the-anti-arrhythmia-effect-of-kordaron-and-novocainamide-by-laser-biostimulation-therapy-in-a-combined-program-for-treating-refractory-tachyarrhythmias
#16
COMPARATIVE STUDY
V A Bobrov, I V Galichanskiĭ, E V Bobrova, I A Mikhalkin, I G Kupnovitskaia, V N Zalesskiĭ
Antiarrhythmic action of He-Ne laser in combination with novocainamid and cordaron has been tried in the framework of the program on combined treatment of tachyarrhythmia. He-Ne laser irradiation has been found to optimize in refractory patients the effect of novocainamid which arrests the paroxysms and of cordarone which prevents paroxysms of atrial tachycardia, fibrillation, flutter.
1993: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/7354588/-late-arrhythmias-in-myocardial-infarct
#17
V M Zhivoderov, V L Doshchitsin, Z I Dunaeva, S P Kolomeĭtseva, V I Nazarova
The authors had 75 patients with myocardial infarction under observation. After the 15th day of the disease various disorders of cardiac rhythm and conductivity were revealed in 85% of patients during cardiomonitor surveillance. The most frequent occurrences were ventricular extrasystole (72.5%), sinus bradycardia (40%) and atrial extrasystole (37.5%). Primary ventricular fibrillation was noted in 4 (5.3%) patients two of whom were resuscitated. In 50 patients with myocardial infarction of more than one month duration disorders of cardiac rhythm during physical load were studied (dosed walking under telectrocardiographic control and/or on a treadmill)...
January 1980: Kardiologiia
https://www.readbyqxmd.com/read/6349912/amiodarone-a-unique-antiarrhythmic-agent
#18
REVIEW
G E Sloskey
The chemistry, pharmacology, pharmacokinetics, clinical use and efficacy, adverse effects, and dosage of amiodarone, an investigational antiarrhythmic agent, are reviewed. Amiodarone hydrochloride (L3428, Cordarone; Labaz Laboratories) is a benzofuran derivative and contains iodine. Amiodarone is a noncompetitive antagonist of alpha- and beta-adrenergic receptors. It is a type III antiarrhythmic agent and causes prolongation of the action potential of atrial and ventricular tissue. The drug is incompletely and variably absorbed following oral administration; bioavailability ranges from 22 to 86%...
July 1983: Clinical Pharmacy
https://www.readbyqxmd.com/read/6193597/-characteristics-of-action-and-efficacy-of-cordarone-in-permanent-auricular-fibrillation-and-extrasystole-in-elderly-and-aged-patients
#19
O V Korkushko, A G Butenko
No abstract text is available yet for this article.
1983: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/6179074/-comparative-evaluation-of-the-effectiveness-of-different-treatment-methods-of-atrial-fibrillation-in-thyrotoxicosis-patients
#20
COMPARATIVE STUDY
A F Litvinenko, N V Ramashkin, V A Oleĭnik, S M Lisianskaia, I M Krivoruk
Comparative data are presented on the treatment of auricular fibrillation in 105 patients with severe thyrotoxicosis. All the patients were divided into 3 groups to evaluate the effectiveness of the treatment: the 1st group of 45 patients, given complex therapy (mercazolyl, diiodotyrosine, cardiac glycosides, potassium drugs, ATF, cocarboxylase); the 2nd group of 40 subjects, treated with inderal in a dose of 80 to 120 mg during 7 days, followed by complex therapy; the 3d group of patients given complex therapy and cordaron...
May 1982: Problemy E̊ndokrinologii
keyword
keyword
105594
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"